Projekt
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer
Abgeschlossen · 2008 bis 2009
Ruhstaller Thomas, Räss Andrea
Art
Reichweite
Bereiche
Status
Start
Ende
Finanzierungsart
Studiendesign
Schlagwörter (Tags)
Projektpartner
Kurzbeschreibung/Zielsetzung
Breast cancer is the second leading cause of cancer-related death in women today (after lung cancer) and is the most common cancer among women worldwide. According to the World Health Organization (WHO), more than 1.2 million people will be diagnosed with breast cancer worldwide in 2005 (Imaginis 2005).
The risk of developing breast cancer increases with age with about two thirds of breast cancers occurring in postmenopausal women. Endocrine therapy is the most important systemic treatment for patients with hormone receptor-positive tumors, which account for two thirds of
breast cancers.